Primary Site >> Liver Cancer
Gene >> TSC2
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
|
Ref: Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. PMID: 19584242 |
Ref: Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways. PMID: 19723512 Ref: Suppression of tumor suppressor Tsc2 and DNA repair glycosylase Nth1 during spontaneous liver tumorigenesis in Long-Evans Cinnamon rats. PMID: 20033472 |
Ref: Allicin induces p53-mediated autophagy in Hep G2 human liver cancer cells. PMID: 22860996 |
Ref: Azathioprine desensitizes liver cancer cells to insulin-like growth factor 1 and causes apoptosis when it is combined with bafilomycin A1. PMID: 23958494 |
Ref: Correlation between tuberous sclerosis complex 2 and glycogen synthase kinase 3 beta levels, and outcomes of patients with hepatocellular carcinoma treated by hepatectomy. PMID: 24119083 Ref: Cryptotanshinone induces G1 cell cycle arrest and autophagic cell death by activating the AMP-activated protein kinase signal pathway in HepG2 hepatoma. PMID: 24173372 Ref: A unique amidoanthraquinone derivative displays antiproliferative activity against human hormone-refractory metastatic prostate cancers through activation of LKB1-AMPK-mTOR signaling pathway. PMID: 25005758 |
Ref: mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma. PMID: 24925055 Ref: Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. PMID: 25724664 Ref: Effects of fucoidan on proliferation, AMP-activated protein kinase, and downstream metabolism- and cell cycle-associated molecules in poorly differentiated human hepatoma HLF cells. PMID: 25776104 Ref: SC-III3, a novel scopoletin derivative, induces autophagy of human hepatoma HepG2 cells through AMPK/mTOR signaling pathway by acting on mitochondria. PMID: 25964188 Ref: Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. PMID: 26099527 Ref: Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade. PMID: 26257239 Ref: Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling. PMID: 27551480 |
Ref: Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling. PMID: 26879559 Ref: Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. PMID: 27130844 Ref: Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma. PMID: 27751352 |
Ref: TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication. PMID: 27974549 Ref: Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. PMID: 28532995 Ref: Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1(+/-) Mice. PMID: 28844017 |
Ref: TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex. PMID: 28967907 Ref: Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC). PMID: 29720580 Ref: PTEN Expression, Not Mutation Status for TSC1, TSC2 or mTOR, Correlates With Outcome on Everolimus in Patients With Renal Cell Carcinoma Treated on RECORD-3. PMID: 30327302 |